Hans Clevers

Venture Partner at LSP Management Group BV

Hans Clevers

Hans Clevers

Venture Partner at LSP Management Group BV

Overview
Career Highlights

The Royal Netherlands Academy of Arts & Sciences
Surrozen, Inc.
Ubiquitous Systems Ltd.

RelSci Relationships

3360

Number of Boards

9

Birthday

1958

Age

62

Number of Awards

5

Relationships
RelSci Relationships are individuals Hans Clevers likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at LSP Management Group BV

Relationship likelihood: Strong

Director, Chairman-Research & Development at Bridgebio Pharma LLC

Relationship likelihood: Strong

Chief Executive Officer at Roche Holding AG

Relationship likelihood: Strong

Former Founder & Director at Peloton Therapeutics, Inc.

Relationship likelihood: Strong

Professor & Chairman-Molecular Genetics Department at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Director at Kyoto University - Center for iPS Cell Research and Application

Relationship likelihood: Strong

Director, Chief Medical Officer & Executive Vice President at Genentech, Inc.

Relationship likelihood: Strong

Senior Advisor, Life Sciences Team at Frazier Healthcare Partners

Relationship likelihood: Strong

Chief Financial & Information Technology Officer at Roche Holding AG

Relationship likelihood: Strong

Head, Research & Early Development at Genentech, Inc.

Relationship likelihood: Strong

Paths to Hans Clevers
Potential Connections via
Relationship Science
You
Hans Clevers
Venture Partner at LSP Management Group BV
Education
PhD
Class of 1985

Utrecht University is a university in Utrecht, the Netherlands. It is one of the oldest universities in the Netherlands and one of the largest in Europe.

Career History
Leader, Clevers Group
Current
Venture Partner
Current

LSP is an active, long-term manager which invests in highly innovative early- to mid-stage life science companies in Europe and the US, focusing on human life sciences investments in Europe and on agriculture, bioenergy, food, nutrition and wellness in the US.The majority of the firm's proprietary deal flow originates from personal initiative, university contacts, and their international network of contacts in the scientific and financial communities. They typically take the role of lead investor, aiming to create optimal value in each investment by assigning an experienced partner to the investee company's supervisory board to support the management team in developing strategic plans, operating priorities and exit scenarios.Throughout the period between closure and exit, LSP provides their expertise and that of their networks in science, medicine and the pharmaceuticals industries to the investee company, aiming to form a strong alliance with the company's executive team to develop their strategy, priorities and associated goals.

Advisor
Current

Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America.They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems.Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing.

Boards & Committees
Member, Scientific Advisory Board
Prior

Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America.They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems.Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing.

Member, Selection Committee
2013 - Current

The Breakthrough Prize in Life Sciences is founded by Art Levinson, Sergey Brin, Anne Wojcicki, Mark Zuckerberg and Priscilla Chan, and Yuri Milner to recognize excellence in research aimed at curing intractable diseases and extending human life. The prize is administered by the Breakthrough Prize in Life Sciences Foundation, a not-for-profit corporation dedicated to advancing breakthrough research, celebrating scientists and generating excitement about the pursuit of science as a career.

Investments
Details Hidden

Surrozen, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA.

Awards & Honors
2013
Breakthrough Prize in Life Sciences
2012
Leopold Griffuel Prize
2012
Dr A.H. Heineken Prize, Medicine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hans Clevers. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hans Clevers's profile does not indicate a business or promotional relationship of any kind between RelSci and Hans Clevers.